Real world study on the efficacy and safety of Shenqi Jiangtang tablets in the treatment of type 2 diabetes mellitus

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2100004820

Enrollment

Unknown

Registered

2021-03-23

Start date

2021-04-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Observation group:Add Shenqi Jiangtang Tablet to hypoglycemic Western Medicine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the diagnostic criteria of Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 Edition); 2. Aged 18-75 years; 3. 7% < HbA1c <= 10%; 4. Patients agreed and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Blood glucose >= 13.57mmol/l; 2. Abnormal liver and kidney function: ALT or ast > 2 x ULN or TBIL > 2 x ULN; Cr > 1 x ULN or CCR < 60ml / min; 3. Pregnant or lactating women within half a year; 4. Allergic constitution or known allergy to the drugs and their components used in this test; 5. Patients considered unsuitable by the researchers.

Design outcomes

Primary

Measure	Time frame
proportion of HbA1c<=7%;HbA1c;FPG;	—

Countries

China

Contacts

Public ContactEnfeng Song, Ling Gao

People's Hospital of Wuhan University

16765084@qq.com+86 15307143917, +86 15927469449

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026